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Vascular smooth muscle cellsAngiotensin II (Ang II)-elicited excessive proliferation, hypertrophy and migration of vascular smooth muscle
cells (VSMCs) are vital to the pathogenesis of atheroclerosis. Glutathione S-transferase pi (GSTpi) exists exten-
sively in various kinds of cells and protects cells against different stresses. However, knowledge remains limited
about what GSTpi acts in VSMCs. We investigated the effect of GSTpi on Ang II-induced VSMC proliferation,
hypertrophy and migration and its latent mechanism. Overexpression and RNAi experiments demonstrated
that GSTpi inhibited Ang II-induced proliferation, hypertrophy andmigration of VSMCs and arrested progression
of cell cycle from G0/G1 to S phase. Immunoprecipitation, mass spectrometry and confocal microscopy analyses
showed that GSTpi directly associated with signal transducer and activator of transcription 3 (STAT3) to prevent
Ang II-triggered binding of Src to STAT3 and thus suppressed Ang II-stimulated phosphorylation and nuclear
translocation of STAT3, as well as cyclin D1 expression. In contrast, GSTpi didn't affect Ang II-activated extracel-
lular signal-regulated kinase (ERK1/2). GSTpi acts as a negative regulator to prevent Ang II-triggered proliferative
signaling in VSMCs, suggesting that it may protect vessels against the stresses associated with atherosclerosis
formation.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Atherosclerosis is a leading cause of morbidity and mortality in the
world. During the progression and development of atherosclerosis,
vascular smooth muscle cells (VSMCs) undergo phenotypic changes
from a quiescent contractile state to a more invasive, synthetic, and
proliferative state [1]. Abnormal proliferation and migration of VSMCs
in response to endothelial cell injury are major contributors to thear smooth muscle cells; GSTpi,
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ights reserved.development of atherosclerosis [2]. Histological studies have displayed
that in the center of atheroma, foamcells and extracellular lipid droplets
form a core regionwhich is surrounded by a cap of VSMCs and collagen-
rich matrix.
Angiotensin II (Ang II), the main peptide hormone of the renin–
angiotensin–aldosterone system (RAAS), is an important regulator in
the cardiovascular system. Ang II induces smooth muscle cell growth,
hypertrophy, cell migration, and events that contribute to cardiovascu-
lar disease progression [3,4]. In vitro and in vivo investigations have
demonstrated a variety of mechanisms by which Ang II may promote
atherogenesis through induction of proliferation, hypertrophy and
migration of VSMCs, oxidative stress, adhesion and chemoattractant
molecules and cytokines [4,5]. Signal transducer and activator of
transcription 3 (STAT3) regulates transcription of various genes related
with in cell proliferation [6] and migration [7], which can be activated
by its upstream kinase Src or JAKs [8,9]. Ang II stimulates STAT3
phosphorylation at tyrosine 705 and promotes it to translocate to the
nucleus, where it trans-activates several target genes involved in prolif-
eration and cell survival [10]. Blocking STAT3 signaling effectively abol-
ishes the proliferative response to Ang II [11,12]. Via promoting STAT3
activation, Ang II leads to VSMC proliferation, hypertrophy and migra-
tion [13,14].
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family of isozymes that catalyze the nucleophilic attack of the sulfur
atom of glutathione (GSH) on electrophilic groups of substrate mole-
cules [15]. Besides, GSTs also appear to regulate cellular signal pathway
via their non-catalytic ligand-binding activity [16]. GSTpi (GSTπ) is the
most prevalent isozyme inmammalian cells. Itmay act as an endogenous
negative regulator of the c-Jun NH2-terminal kinases (JNKs) signaling
[17,18] and inhibit tumor necrosis factor alpha (TNF-α)-induced apopto-
sis through associating with tumor necrosis factor receptor-associated
factor 2 (TRAF2) [19].
Our previous studies both at cell and animal levels demonstrate that
GSTpi plays an anti-inﬂammatory role in response to LPS stimulation.
Recent publications indicate that GSTpi contributes to the regulation of
proliferation of embryo ﬁbroblasts and increases of myeloproliferation
[20,21]. TLK199 (g-glutamyl-S-(benzyl) cysteinyl-R-phenyl glycine
diethyl ester), an inhibitor of GSTpi, could stimulate both lymphocyte
production and bone marrow progenitor proliferation. TLK199 is now
being developed for the treatment of myelodysplastic syndrome [22].
GSTpi is also shown to be involved in the antiproliferative action of
butyrate, a bacterial fermentation product of dietary ﬁber, in VSMCs
[23]. Nevertheless, whether and how GSTpi regulates the proliferation,
hypertrophy and migration of VSMCs remain poorly recognized and
understood. In this study, we demonstrate that GSTpi blocks Ang II–
Src–STAT3pathway throughdirectly binding to STAT3, and consequently
prevents Ang II-induced VSMC proliferation and migration. Our study
indicates a novel effect of GSTpi on protecting blood vessels against
Ang II induced remodeling.
2. Material and methods
2.1. Reagents and plasmids
pcDNA3–Xpress-GSTpi and pcDNA3–Flag-GSTpi were kept in
our laboratory. STAT3-Luc reporter vector was kindly provided by
Dr Chang Zhijie from Department of Biological Sciences and Biotechnolo-
gy, State Key Laboratory of Biomembrane and Membrane Biotechnology,
Tsinghua University. pcDNA3–Flag-GSTpi (Y7F) and pU6–GSTpi–RNAi
were constructed. All plasmids were puriﬁed using the Endofree
Plasmid Preparation kit (Qiagen, Germany). Anti-phospho-STAT3
(Tyr705), anti-phospho-STAT1 (Tyr701), anti-phospho-JAK2 (Tyr1007/
1008), anti-phospho-Src (Tyr416), Anti-phospho-ERK1/2 (T202/Y204),
ERK1/2, Src and FLAG antibodies were obtained from Cell Signaling
Technology Inc. (Danvers, MA, USA). STAT3 and A/G beads were from
Santa Cruz Biotechnology (Texas, TX, USA). Monoclonal antibody
against GSTpi was from Becton, Dickinson and Company (San Diego,
CA, USA). The IRdye 800 conjugated IgG secondary antibodies were
purchased from Rockland (Gilbertsville, PA, USA). Lamin B, GAPDH
and β-actin antibodies were obtained from Bioworld Technology, Inc.
Angiotensin II, CHX, AG490 and SU6656 were purchased from Sigma
(St. Louis,MO). Transwellwere purchase fromMillipore (Massachusetts,
MA, USA).
2.2. Primary VSMC culture and transfection
VSMCs were harvested from normal rat aortas using the explant
technique [24]. The VSMCs were cultured routinely in Dulbecco's
modiﬁed Eagle's medium (DMEM; Hyclone Laboratories Inc., USA) con-
taining 10% FBS, supplemented with penicillin (100 U/ml) and strepto-
mycin (100 μg/ml) at 37 °C with a humidiﬁed atmosphere of 5% CO2.
The primary VSMCs were identiﬁed using smooth muscle α-actin anti-
body. For all experiments, VSMCs (2–5 passages) were used following
by quiescence for 12 h. Primary VSMCs were cultured routinely in
DMEM containing 20% fetal bovine serum (FBS), penicillin (100 U/ml),
and streptomycin (100 μg/ml) at 37 °C in a humidiﬁed atmosphere of
5% CO2 and 95% air.The cells were seeded into indicated plates 24 h prior to transfection
at approximately 80% conﬂuence. Transient transfectionwas performed
using X-tremeGENE HP DNA Transfection Reagent (Roche Molecular
Biochemicals, Germany) according to the manufacturer's instructions.
In all cases, the total amount of DNA was normalized by addition of
empty control plasmids.
2.3. Cell proliferation assay
Cell proliferation assays were performed by 3-(4,5-Dimethyl-2-
thiazolyl)-2,5-diphenyl-tetrazolium bromide (MTT; Sigma-Aldrich,
St Louis, MO, USA) and direct cell counting assays as previously
described [24]. For the MTT assay, VSMCs (1 × 104) were plated in trip-
licate into 96-well plates and were transfected with different doses of
indicated plasmids for 36 h. Following treatment with Ang II (100 nM)
for 36 h, cells were incubated with 10 μl MTT (5 mg/ml) per well for
4 h, and then dissolve by dimethylsulfoxide (DMSO). The absorbance
of each well was measured at 570 nm using an EL × 800 Universal
Microplate Reader (Bio-Tek, Inc.). The proliferation amount of the con-
trol VSMCswas indicated as 100% and results were expressed as relative
proliferation. For the cell counting assay, VSMCs (5 × 104/ml) were
seeded in 24-well plates. The number of cells in each well was counted
after the similar treatment.
2.4. VSMC migration assay
Migration assays were performed by using 24-well cell culture
inserts with 8.0 μm pore size transwell culture chambers (Corning, NY,
USA) and measured as previously described [24]. VSMCs (4 × 104)
were transfected with indicated plasmids for 36 h and were seeded
into chamber inserts. Then, Ang II (100 nM) was added to the lower
chamber to induce cell migration. After 4 h of incubation at 37 °C in
5% CO2, non-migrating cells were removed from the upper surface of
the transwell membrane with a cotton swab, and migrating cells on
the lower surface of themembranewere then ﬁxedwith 4% paraformal-
dehyde and stained by hematoxylin and eosin. Bright-ﬁeld images were
selected randomly ﬁve squares per well with a lightmicroscope at ×100
magniﬁcation. The number of migrated cells was counted and the
results were expressed as relative migration rate.
2.5. Cell cycle analysis
VSMCs were plated in 6-well plates at 1 × 105 cells/well, and
transfected with indicated doses of plasmids. After 36 h, VSMCs were
quiesced in 0.5% FBS for 12 h followed by incubation with 100 nM
Ang II for 24 h. VSMCs were trypsinized, and ﬁxed in 70% ethanol for
12 h. The ﬁxed cells were stained with propidium iodide (PI) and
analyzed on a FACScan ﬂow cytometer (Becton Dickinson, USA). The
percentages of cells in different phases of the cell cycle were analyzed
using the software of FV10-ASW viewer.
2.6. [3H]Leucine incorporation
To measure hypertrophy of VSMCs, cells plated at low density were
transfected with indicated plasmids for 36 h, and were made quiescent
by 24 h in DMEM containing 0.1% FBS. Twenty-four hours before har-
vest, VSMCs were incubated with [3H]leucine (2 μCi/ml, PerkinElmer)
in the presence or absence of 100 nM Ang II. Cells were then washed
twice with ice-cold PBS and were dissolved in RIPA lysis. Liquid scintil-
lation cocktail (Optiphase Supermix, PerkinElmer) was added to the
wells. Radioactivity was determined using a liquid scintillation counter.
2.7. Immunoprecipitation and immunoblot analysis
Cell lysates were collected by immunoprecipitation and immuno-
blotting as previously described [19]. Cells were solubilized in lysis
456 D. Chen et al. / Biochimica et Biophysica Acta 1843 (2014) 454–463buffer containing 20 mM Tris (pH 7.5), 135 mM NaCl, 2 mM EDTA,
2 mMDTT, 25 mM β-glycerophosphate, 2 mM sodium pyrophosphate,
10% glycerol, 1% Triton X-100, 1 mM sodium orthovanadate, and
complete protease inhibitor cocktail for 20 min on ice. Lysates are
centrifugated (15,000 ×g) at 4 °C for 10 min. Proteins were immuno-
precipitated with indicated antibodies respectively. Protein A/G PLUS-
agarose beads (Santa Cruz Biotechnology, USA) were incubated with
proteins for 2 h andwashed four timeswith the lysis buffer. The precip-
itates were subjected to 12% SDS-polyacrylamide gel, and then trans-
ferred to nitrocellulose membranes. The IRdye 800 conjugated IgG
secondary antibody was used respectively against primary antibody.
The proteins were visualized using Odyssey infrared imaging system
(LI-COR Biosciences, USA).
2.8. Cytosolic and nuclear protein preparations
Cytosolic and nuclear proteins were extracted by NE-PER nuclear
and cytoplasmic extraction kit from Thermo Fisher Scientiﬁc Inc.
(Massachusetts, MA, USA) according to themanufacturer's instructions.
VSMCswere collected in phosphate buffered solution (PBS) andwashed
twice with cold PBS by centrifuging at 300 ×g for 3 min. All procedures
were carried out at 4 °C unless otherwise mentioned.
2.9. Immunoﬂuorescence confocal laser scanning microscopy
VSMCs grown on Lab-Tek Chamber Slides (Nalge Nunc Int,
Naperville, IL), were ﬁxed with 4% paraformaldehyde for 15 min at
room temperature. Nonspeciﬁc reactions were blocked with PBS
containing 5% bovine serum albumin and 5% fetal calf serum for 1 h.
The specimens were incubated with the primary antibodies for 12 h.
The remaining procedures were performed in the absence of bright
light. VSMCs were treated with the associated secondary antibodies
respectively (Invitrogen, Carlsbad, CA, USA) after washing with
phosphate-buffered saline (PBS). Slides were counterstained with
0.1 μg/ml DAPI and examined using the Nikon A1 confocal laser micro-
scope system (Tokyo, Japan).
2.10. Luciferase reporter assays
VSMCs cultured in 12-well plates were co-transfected with STAT3
target sequence-linked-luciferase reporter DNA and β-galactosidase
reporters, together with indicated plasmids for 36 h. Following treat-
ment with 100 nM Ang II for 8 h, protein samples were prepared and
the luciferase activity was measured using Luciferase Assay System
(Promega, Madison, WI, USA). Luciferase activity was analyzed by the
GloMax® 96 microplate Luminometer using 100 μl cell lysate and an
equal volume of luciferase substrate.
2.11. Mass spectrometry analysis
Proteins were immunoprecipitated using anti-GSTpi antibody.
Protein A/G PLUS–agarose beads were incubated with proteins for 2 h
and washed four times with the lysis buffer. The GSTpi complex was
eluted from beads using the methods reported previously [25]. Then,
the endogenous GSTpi complex was analyzed in linear mode by
AXIMA MALDI-TOF (Shimadzu Kratos, Manchester, UK).
2.12. Detection of S-glutationylation
Cells were lysed in non-reducing lysis buffer containing 20 mM Tris
(pH 7.5), 150 mMNaCl, 2 mM sodium pyrophosphate, 10% glycerol, 1%
Triton X-100, 1 mM sodium orthovanadate, and complete protease
inhibitor cocktail for 20 min on ice. Lysates were centrifugated
(15,000 ×g) at 4 °C for 10 min. Equivalent amounts of protein were
electrophoretically resolved under non-reducing conditions on 10%
SDS-polyacrylamide gels, and then transferred to nitrocellulosemembranes. Membranes were incubated with monoclonal anti-
glutathionylated protein antibodies (Abcam, MA). After washing 3
times with TBST, an immunoblot was developed with anti-mouse
IRdye 800 secondary antibody. The proteins were visualized using
Odyssey infrared imaging system (LI-COR Biosciences, USA).
2.13. Statistical analysis
Data were expressed as mean ± SEM. Statistical analysis was per-
formed using GraphPad Prism 4.0. Data were analyzed by Student's t
test or by analysis of variance (ANOVA). ANOVA was performed on
data at a minimum p b 0.05 threshold, followed by the Bonferroni
correction for post-hoc t tests.
3. Results
3.1. GSTpi prevents VSMC proliferation,migration and hypertrophy induced
by Ang II
Ang II is a mitogen responsible for VSMC proliferation and is
involved in the development of vascular proliferative lesions observed
in atherosclerosis and restenosis after angioplasty. We observed the
effects of GSTpi on Ang II-induced VSMC proliferation. MTT assay
showed that Ang II treatment accelerated the proliferation of VSMCs
from 100% to 190% (Fig. 1A), whereas overexpression of GSTpi time-
and dose-dependently inhibited Ang II-stimulated cell proliferation
(Fig. 1A and B). Data from cell cycle analysis demonstrated that the per-
centage of VSMCs in S phase increased 24 h after Ang II treatment, and
this progression of cell cycle from G0/G1 to S phase was arrested by
overexpression of GSTpi (Fig. 1C). Since cyclin D1 is required for the
cell cycle G1/S transition, we transfected GSTpi to VSMCs and then
detected the level of cyclin D1 in cells after Ang II stimulation. Ang
II-induced upregulation of cyclin D1 was prevented by GSTpi signiﬁ-
cantly (Fig. 1D). Migration of VSMCs is a key event in neointimal forma-
tion and atherosclerosis [2]. We next performed transwell migration
assay to evaluate the effect of GSTpi on migration of VSMCs. The results
showed that Ang II-stimulated VSMC migration (1.5 fold increase over
the basal level) was apparently inhibited by overexpression of GSTpi
(Fig. 1E).
In addition to hyperplasia and migration, Ang II also causes VSMC
hypertrophy during atherosclerosis progress [4]. To test whether
GSTpi was able to attenuate Ang II-triggered hypertrophic response in
VSMCs, cellular hypertrophywas analyzed by [3H]leucine incorporation
and volumemeasure. Ang II-induced increase of [3H]leucine incorpora-
tion into protein (Fig. 2A) and enlarge of cellular volume (Fig. 2B) was
blocked by GSTpi.
To conﬁrm the inhibitory role of GSTpi in Ang II-triggered prolifera-
tion and migration of VSMCs, we constructed the pU6–GSTpi RNAi
expression vector to silence GSTpi gene in VSMCs (Supplementary
Fig. IA and B). The exact sequences of shRNAwere shown in Supplemen-
tary Table 1. GSTpi expressionwas reduced by 65% in VSMCs transfected
with the GSTpi RNAi vector compared with non-transfected or mock-
transfected cells (Fig. 3A). MTT and FACScan ﬂow cytometry analysis
showed that knockdown of GSTpi enhanced Ang II-induced prolifera-
tion (Fig. 3B) and the cell cycle G1/S transition (Fig. 3C). Transwell
assay also displayed that GSTpi RNAi promoted Ang II-induced migra-
tion of VSMCs (Fig. 3D). All together, these data indicated that GSTpi
negatively regulated Ang II-induced proliferation, migration and hyper-
trophy of VSMCs, suggesting that GSTpi could protect VSMCs against the
stimulation of Ang II.
To observe whether GSTpi worked via its enzyme activity or non-
catalytic ligand-binding activity [15,16],we constructed the catalytically
inactive mutant pcDNA3–GSTpi (Y7F, phenylalanine replaced tyrosine
in the seventh amino-terminal position) expression vector (Supple-
mentary Fig. IIA and B) and compared regulation activity of wild type
GSTpi with GSTpi (Y7F). The result showed that GSTpi (Y7F) could
Fig. 1. Effects of overexpressed GSTpi on Ang II-induced proliferation and migration of VSMCs. (A) VSMCs were transfected with pcDNA3 or GSTpi, and after 36 h cells were treated with
Ang II for 0, 24, 36 and 48 h and thenwere counted. (B) VSMCswere transfectedwith pcDNA3orGSTpi (0.5, 1 or 2 μg/ml). After 36 h, VSMCswere incubatedwith Ang II for 48 h andwere
subjected to MTT assay. Data were obtained from three independent experiments. (C) VSMCs were transfected with pcDNA3 or GSTpi (0.5, 1 or 2 μg/ml) for 36 h. Cell cycle progression
was analyzed by ﬂow cytometry using the DNA stain PI 24 h after Ang II stimulation. (D) VSMCs were transfected with indicated doses of GSTpi. After 36 h, VSMCs were incubated with
Ang II for 24 h followed by immunoblotting using the cyclin D antibody. Experiments were performed in triplicate. (E) VSMCs were transfected with control or GSTpi plasmids and then
incubated with Ang II for 4 h. Cellular migration was examined and demonstrated as relative migration rate of control group.
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cyclin D1 as well (Supplementary Fig. IIC and D), suggesting that cata-
lytic activity of GSTpi was unnecessary for its inhibitory effect on Ang
II-induced proliferation of VSMCs.
3.2. GSTpi inhibits Ang II-induced STAT3 activation and nuclear translocation
in VSMCs
Since STAT3 is thought to play an essential role in Ang II-induced cell
proliferation, migration and hypertrophy, VSMCswere transfected withdifferent dose of Xpress-GSTpi plasmid followed by treatmentwith Ang
II for 60 min and then were subjected to immunoblotting by using
indicated antibodies. The results demonstrated that Ang II induced an
apparent increase of STAT3 phosphorylation in VSMCs, and overexpres-
sion of GSTpi restrained STAT3 phosphorylation in a dose-dependent
manner (Fig. 4A). Previous report has indicated that p60 Src but not
JAK2 was required for Ang II-induced tyrosine phosphorylation of
STAT3 in VSMCs [26]. Consistently, our experiments showed that Src
family kinase inhibitor SU6656 but not the Janus-activated kinase 2
(JAK2) inhibitor AG490 suppressed Ang II-induced phosphorylation of
Fig. 2. GSTpi inhibits Ang II-induced hypertrophic response in VSMCs. (A) VSMCs were transfected with pcDNA3 or GSTpi, and after 36 h VSMCs were incubated with [3H]leucine
(2 μCi/mL) in the presence or absence of 100 nMAng II for 24 h and thenweremeasured in the liquid scintillation spectrophotometer. Data represent the fold of [3H]leucine incorporation
compared with control. (B) VSMCs were transfected with pcDNA3 or GSTpi for 36 h, and then VSMCs were incubated with Ang II for 24 h and then were digested by 0.25% trypsin and
re-suspend. Bright-ﬁeld images were selected randomly ﬁve squares per well with a light microscope at ×100 magniﬁcation. The diameter of cells was measured by Image-Pro Plus
software. Data were obtained from three independent experiments and were expressed as relative hypertrophy fold.
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of GSTpi in Ang II-induced STAT3 activation, VSMCs were stimulated
with Ang II for indicated time under a GSTpi overexpression or RNAi
condition and then were subjected to immunoblotting by using phos-
phorylated STAT3 or STAT1 antibody respectively. Ang II-induced
STAT3 phosphorylation was inhibited by GSTpi overexpression and
was enhanced byGSTpi RNAi respectively (Fig. 4B and C). Similar results
were obtained from analysis of STAT3 luciferase reporter activity
(Fig. 4D and E). Moreover, GSTpi (Y7F) also suppressed Ang II-
stimulated STAT3 activation (Supplementary Fig. IIE). GSTpi did not
inﬂuence Ang II-mediated activation of extracellular signal-regulated
kinase (ERK1/2) (Fig. 4F). These results demonstrated that GSTpiFig. 3. Inﬂuence of GSTpi knockdown on VSMC proliferation and migration. (A) VSMCs were
immunoblotting to determine the efﬁciency of GSTpi suppression. (B) VSMCs were transfe
proliferationwas determinedbyMTT. (C) Cellswere transfectedwith control orGSTpi RNAi vect
using DNA stain PI. (D) VSMCs were transfected with pU6 or pU6–GSTpi RNAi and stimulatedmight prevent Ang II-induced VSMCproliferation, migration and hyper-
trophy through inhibiting STAT3 activation.
Cytosolic phosphorylated STAT3 forms homo- and hetero-
dimerization and then translocates into the nucleus to activate tran-
scription. Ang II stimulation resulted in a translocation of STAT3 into
the nucleuswithin 60 min in VSMCs (Supplementary Fig. IV).We there-
fore transfected GSTpi into VSMCs and then treated cells with Ang II for
60 min followed by cytosolic and nuclear protein extraction. Immuno-
blotting assay showed that Ang II-triggered STAT3 nuclear translocation
was inhibited by overexpression of GSTpi (Fig. 5A). Confocal laser scan-
ningmicroscopy further displayed the inhibitory effects of GSTpi on Ang
II-induced nuclear localization of STAT3 (Fig. 5B). On the other hand,transfected with either pU6 or pU6–GSTpi RNAi, and after 36 h, cells were subjected to
cted with GSTpi RNAi vector (2 μg/ml) and then incubated with Ang II for 48 h. VSMC
or. After 24 h incubationwith Ang II, cell cycle progressionwas analyzedbyﬂowcytometry
with Ang II for 4 h followed by transwell assay.
Fig. 4. Effects of GSTpi on Ang II-induced STAT3 phosphorylation. (A) VSMCs were transiently transfected with Xpress-GSTpi (0.5, 1, or 2 μg/ml) or empty vectors. After 36 h, cells were
treatedwith (+) orwithout (−) 100 nMAng II for 60 min followed by immunoblotting using indicated antibodies. (B) VSMCswere transiently transfected with Xpress-GSTpi (2 μg/ml)
or pcDNA3, and after 36 h cells were stimulated with 100 nMAng II for indicated time followed by immunoblotting using phospho-STAT3 (Tyr705), phospho-STAT1 (Tyr701), STAT3, or
STAT1 antibodies. GAPDH expression was measured to conﬁrm the equal amount of protein. Results shown are representative of three experiments. (C) VSMCs were transfected with
GSTpi RNAi (2 μg/ml) or pU6 (negative control) and then stimulated with 100 nM Ang II for 0, 0.5, 1 or 2 h respectively. Cells were subjected to immunoblotting using speciﬁc
phospho-STAT3 (Tyr705), phospho-STAT1 (Tyr701), STAT3 or STAT1 antibodies. Results shown are representative of three experiments. (D) VSMCs were co-transfected with STAT3
luciferase reporter plasmids and GSTpi or pcDNA3. Luciferase activity was measured 8 h after Ang II treatment. All values were normalized with β-gal activities. (E) VSMCs were
co-transfectedwith STAT3 luciferase reporter DNA and GSTpi RNAi or vector plasmids. Luciferase activity wasmeasured 8 h after Ang II treatment. (F) VSMCswere transiently transfected
with Xpress-GSTpi (2 μg/ml) or pcDNA3, and after 36 h cells were stimulated with 100 nM Ang II for 0, 5, 15, 30, 45, and 60 min followed by immunoblotting using phospho-ERK1/2
(T202/Y204), and ERK1/2 antibodies. GAPDH expression was measured to conﬁrm the equal amount of protein. Results shown are representative of three experiments.
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copy demonstrated that knockdown of GSTpi by RNAi enhanced Ang
II-triggered STAT3 nuclear translocation (Fig. 5C and D).
3.3. GSTpi associates with STAT3 to prevent Ang II-Src-STAT3 signaling
in VSMCs
Above data suggested that catalytic activity of GSTpi was not essen-
tial for inhibiting Ang II-induced proliferation of VSMCs (Supplementary
Fig. II). We thus investigated the binding activity of GSTpi. In the mass
spectrum of MALDI-TOF (Fig. 6A), we found there were three clear
peaks probably indicated GSTpi and STAT3 complex including GSTpi/
STAT3 (111 kDa), 2GSTpi/STAT3 (135 kDa) and 2STAT3 (176 kDa),
strongly suggesting the binding between GSTpi and STAT3. We then
performed immunoprecipitation and immunoblotting experiments to
detect the speciﬁc association of endogenous GSTpi with STAT3. Lysates
of VSMCs were immunoprecipitated using respective antibodies, and
then the pellets were analyzed by immunoblotting with anti-GSTpi
monoclonal antibody. The results indicated that endogenous GSTpi
combined with STAT3 but not STAT1 or Src in VSMCs (Fig. 6B–D). We
next checked the binding between GSTpi and STAT3 as well as STAT3and Src after Ang II stimulation. In unstimulated cells, endogenous
GSTpi associated with STAT3 and it dissociated from STAT3 60 min
after Ang II treatment. We noticed that as the amount of endogenous
STAT3/GSTpi complex decreased after Ang II stimulation, complex of
STAT3/Src increased (Fig. 6E). The similar results were obtained from
the confocal laser scanning microscopy. In the upper panel of Fig. 6F,
yellow depicted the co-localization of GSTpi and STAT3, but in the
lower panel of Fig. 6F, the color of yellow was not detected, which indi-
cated that Ang II stimulation decreased the co-localization of GSTpi and
STAT3 that existed in unstimulated cells. To determine whether Ang II-
induced decrease amount of GSTpi/STAT3 complex was due to GSTpi
degradation, GSTpi protein level in VSMCs was measured by immuno-
blotting at indicated time after Ang II stimulation in the presence of
cycloheximide (CHX), a protein synthesis inhibitor (Fig. 6G). The results
indicated that Ang II reduced the binding of GSTpi and STAT3 without
altering GSTpi protein level. In order to further analyze the effects of
GSTpi on Ang II-triggered STAT3 and Src interaction, VSMCs were
transfectedwith GSTpi and stimulatedwith Ang II followed by immuno-
precipitation assay. The increased association of Src with STAT3 induced
by Ang II was prevented by forced expression of GSTpi (Fig. 6H). All
together, these data indicated that GSTpi suppressed STAT3 activation
Fig. 5.Effects ofGSTpi on nuclear translocation of STAT3 inVSMCs. (A) VSMCswere transfectedwith Xpress-GSTpi (2 μg/ml) or empty vector for 36 h. Cytoplasmic andnuclear fractions of
VSMCs treated with Ang II (100 nM) were prepared. The lysates were detected by immunoblotting using STAT3 antibody. GAPDH was used as loading controls for cytosolic protein and
Laminin B was used for normalizing nuclear proteins. (B) VSMCs were transfected with either GSTpi or empty expression vectors for 36 h and then were treated with 100 nM Ang II for
60 min. VSMCs were immunostained with STAT3 antibody and then with donkey anti-rabbit Alexa Fluor 555 secondary antibodies. After being stained with DAPI VSMCs were detected
under a confocal microscope. Blue depicts the nucleus and red depicts STAT3 protein. Similar results were obtained in three experiments. (C) VSMCs were transfected with GSTpi RNAi
(2 μg/ml) or empty vector. Cytoplasmic and nuclear fractions of VSMCs were prepared after Ang II treatment for 60 min followed by immunoblot analysis using STAT3 antibody. The
representative Western blot and densitometric results illustrated are mean ± SEM for 3 experiments and are expressed as ratio to control. (D) VSMCs were transfected with GSTpi
RNAi (2 μg/ml) or empty vector and then were treated with 100 nM Ang II for 60 min. VSMCs were visualized by confocal microscopy as described in (B). Similar results were obtained
in three experiments.
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STAT3.
S-glutathionylation is a novel post-translational modiﬁcation
through disulﬁde linkages between GSH and redox-sensitive cysteine
residues within proteins [27]. Catalytically active GSTpi potentiates
S-glutathionylation reactions following oxidative and nitrosative stress
[28]. As shown in Supplementary Fig. V, Ang II led to the increase
of STAT3 S-glutathionylation in VSMCs. But when we raised VSMC
GSTpi protein level through overexpressing GSTpi, Ang II induced
S-glutathionylation STAT3 did not change.3.4. GSTpi also inhibits platelet-derived growth factor (PDGF)-induced
proliferation of VSMCs and STAT3 activation
To detect whether the effect of GSTpi on Ang II/AT1R signaling is
speciﬁc, we further established the inﬂuence of GSTpi on PDGF/PDGFR
(platelet-derived growth factor receptors) caused the proliferation
and STAT3 activation in VSMCs.MTT assay showed that PDGF treatment
led to an increase in the proliferation rate of VSMCs, whereas overex-
pression of GSTpi inhibited PDGF-stimulated cell proliferation
(Fig. 7A). As shown in Fig. 7B, STAT3 activation in VSMCs was assessed
after PDGF incubation. STAT3 phosphorylation was increased 15 min
after PDGF stimulation. PDGF-provoked STAT3 activation and transloca-
tion were prevented by overexpression of GSTpi (Fig. 7B and C), and
STAT3 phosphorylation was enhanced by GSTpi RNAi (Fig. 7D).4. Discussion
VSMCproliferates,migrates to the intima and synthesizes the bulk of
the extra cellular matrix (ECM), which contributes to the thickening of
the artery wall and exacerbating atherosclerotic lesions [1,29]. Ang II
promotes atherogenesis through induction of proliferation, hypertro-
phy and migration of VSMCs [4,5]. In the present study, we found that
GSTpi acted as a critical negative regulator in Ang II-stimulated prolifer-
ation, hypertrophy and migration of VSMCs. GSTpi directly associated
with STAT3 to prevent Ang II-provoked Src-STAT3 signaling. Therefore,
GSTpi suppressed Ang II-stimulated phosphorylation and nuclear trans-
location of STAT3, and as a result inhibited STAT3mediated the prolifer-
ation, hypertrophy and migration of cells.
The overexpression of GSTpi is observed in tumors and can
protect cancer cells from oxidative stress, so most studies about GSTpi
focus on its protective effects on cancer cells. Although GSTpi has been
detected in a variety of normal tissues, its regulatory role in the physio-
logical processes has not been identiﬁed yet. Our previous studies have
demonstrated that GSTpi could suppress inﬂammatory responses
through inhibiting macrophage activation and cytokine release
[30,31]. The antioxidative and anti-inﬂammatory functions of GSTpi
suggest a possibility that GSTpi may protect blood vessels against the
atherogenesis related stresses. In addition, Tew KD's group found that
GSTpi−/−mice showed an increased myeloproliferation and this phe-
nomenon was associated with a deregulation of JNK and Janus kinase/
STAT pathways [20,21]. Their ﬁndings predict another possibility that
Fig. 6. GSTpi interacts with STAT3. (A) The endogenous GSTpi complex was analyzed by MALDI-TOF. (B, C and D) Lysates from VSMCs were subjected to immunoprecipitation with
anti-STAT3 (B), anti-Src (C), anti-STAT1 (D) or control rabbit immunoglobulin G (rIgG). The precipitates were analyzed by immunoblotting with anti-GSTpi antibody. (E) Lysates from
VSMCs stimulated with Ang II or not were subjected to immunoprecipitation with anti-STAT3, and were detected by immunoblotting with anti-GSTpi and anti-Src antibodies.
(F) VSMCs were treated with Ang II or vehicle, and then immunostained with GSTpi and STAT3 antibodies, and then with donkey anti-mouse Alexa Fluor 555 and anti-rabbit Alexa
Fluor 488 secondary antibodies. VSMCs were visualized by confocal microscopy after stained with DAPI. Red depicts GSTpi; green depicts STAT3, and the merge of red and green showed
yellowwhich depicts the co-localization of GSTpi and STAT3. (G) VSMCs were pretreatedwith cycloheximide (CHX, 1 μg/ml) for 1 h, and then incubatedwith Ang II for indicated time in
the presence or absence of CHX. The protein levels of GSTpi and β-actin were determined by immunoblot analysis. (H) VSMCs were transfected with GSTpi or pcDNA and then were
stimulated with Ang II (100 nM) or not. Immunoprecipitation was performed with STAT3 antibody followed by immunoblotting with the anti-Src antibody.
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that GSTpi prevented VSMC proliferation and arrested cell cycle at
G0/G1-phase in response to Ang II treatment.Moreover, GSTpi inhibited
Ang II-induced hypertrophy and migration of VSMCs. These ﬁndings
strongly suggest that GSTpi could protect VSMCs from Ang II stimulated
phenotypic alteration, and as a result, prevent the formation of athero-
mas on the walls of the arteries.
Yang Y et al. showed that GSTmu, another member of GST family,
regulates vascular smooth muscle cell proliferation and migration,
perhaps through its role in handling oxidative stress [32]. GSTmu andGSTpi have a similar structure of C-terminal domain, which implies
some similar properties of these two enzymes [16]. However, the differ-
ent protein binding features between them have also been reported
[19,33]. Previous publication [26] and our observations showed that
Ang II-induced tyrosine phosphorylation of STAT3 in VSMCs was medi-
ated by Src but not JAK2, and preventing Src signaling to STAT3 could
block STAT3 activation elicited by Ang II. Our ﬁndings in the present
study indicate a novel mechanism by which GSTpi negative regulates
Ang II-induced VSMC proliferation, hypertrophy and migration. These
ﬁndings are as follows: GSTpi physically associates with STAT3 in
Fig. 7.GSTpi prevents PDGF-induced VSMC proliferation and the activation and translocation of STAT3. (A) VSMCswere transfectedwith 2 μg/ml pcDNA3 or GSTpi for 36 h. VSMCswere
incubatedwith 100 nMAng II or 20 ng/ml PDGF for 48 h and cellswere subjected toMTT assay. (B) VSMCswere transiently transfectedwith Xpress-GSTpi or pcDNA3, and after 36 h cells
were stimulated with 20 ng/ml PDGF for indicated time followed by immunoblotting using phospho-STAT3 (Tyr705), STAT3, and GSTpi antibodies. GAPDH expression was measured to
conﬁrm the equal amount of protein. (C) VSMCswere transfectedwith Xpress-GSTpi or empty vector for 36 h. Cytoplasmic and nuclear fractions of VSMCs treatedwith PDGF (20 ng/ml)
were prepared. The lysates were detected by immunoblotting using STAT3 antibody. GAPDH was used as loading controls for cytosolic protein and Laminin B was used for normalizing
nuclear proteins. (D)VSMCswere transfectedwithGSTpi RNAi or pU6 and then stimulatedwith 20 ng/ml PDGF for 0, 5, 15 or 30 min respectively. Cellswere subjected to immunoblotting
using speciﬁc phospho-STAT3 (Tyr705), STAT3 or GSTpi antibodies.
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stimulation of Ang II leads to dissociation of GSTpi from STAT3. As
STAT3 separates from the complex of GSTpi and STAT3, Src binds to it
and promotes it phosphorylation and nuclear translocation. Whereas
if we raised GSTpi level in VSMCs by forced expressing GSTpi gene,
Ang II-elicited association of Srcwith STAT3 reduced and then activation
of STAT3was prevented. Our study strongly suggests that GSTpi has po-
tential to contribute to themaintenance of vascular stability and reduce
the possibility of atherosclerosis formation.
In addition to Src/STAT3, JAK2/STAT1 has also been reported to be
involved in the proliferative response of VSMCs to Ang II [9], but Ang
II-induced VSMC proliferation was completely abolished by the electro-
poration either anti-STAT1 or anti-STAT3 antibody. This phenomenon
displays that if one of STAT1 and STAT3 signaling is inhibited, the rest
of them does not mediate Ang II-induced VSMC proliferation. Consis-
tently, although GSTpi does not affect Ang II-induced activation ofSTAT1, it can inhibit Ang II-induced VSMC proliferation through
interacting with STAT3. The identity of STAT1 and STAT3 sequences is
about 55.81%. The protein sequence of STAT1 is only 72% homologous
with STAT3 [34]. Ang II-induced STAT1 activation is JAK2 dependent
[9], whereas, Ang II-induced STAT3 activation is Src dependent in
VSMCs [26]. Themotif of STAT3 required for bindingwith Src is different
from the motif of STAT1 for JAK2 binding. Thus, in the present study,
GSTpi was speciﬁc to associate with STAT3 to prevent the binding
between Src and STAT3.
PDGF, a growth factor, can also lead to VSMC proliferation through
activating STAT3. Since GSTpi directly associated with STAT3 in
VSMCs, it could prevent PDGF-caused STAT3 phosphorylation and
translocation. It is not surprised that GSTpi inhibited both Ang II and
PDGF-induced proliferation and activation of STAT3 in VSMCs. Catalyti-
cally active GSTpi potentiates S-glutathionylation of proteins. In the
present study, GSTpi inﬂuenced the proliferation and migration of
463D. Chen et al. / Biochimica et Biophysica Acta 1843 (2014) 454–463VSMCs and inhibited the activation of STAT3 via its non-catalytic ligand-
binding activity. Thus although the S-glutathionylation of STAT3 was
enhanced slightly by Ang II stimulation, it was not altered by GSTpi
over-expression.
In summary, the current study provides insight into the mechanism
underlying GSTpi protection against Ang II-stimulated proliferation and
migration of VSMCs. Through interacting with STAT3, GSTpi prevents
Ang II-provoked Src-STAT3 signaling and inhibits STAT3 activation,
and as a result arrests progression of cell cycle from G0/G1 to S phase.
GSTpi may act as an important negative regulator in Ang II-stimulated
proliferation and migration of VSMCs. Our ﬁndings suggest a protective
effect of GSTpi on VSMCs to avoid someproliferative stimulation related
with atherogenesis.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamcr.2013.11.024.
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